EMEA reviews policy on conflicts of interest

This article was originally published in SRA

06 Feb 2009
News

Vibha Sharma @ScripRegVibha vibha.sharma@informa.com

Executive Summary

Ongoing discussions on the European Medicines Agency’s policy on handling conflicts of interest relating to experts appointed to the scientific advisory groups that provide advice on specific types of medicinal products or treatments to the agency’s Committee for Medicinal Products for Human Use are likely to lead to a revision of the policy¹.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS114184

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS114184

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

EMEA reviews policy on conflicts of interest

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert